Navigation Links
SNM applauds NAS study showing need to restore federal nuclear medicine research funding
Date:9/20/2007

RESTON, Va. -- Based on the results of a recent National Academy of Sciences report, federal funding for basic molecular imaging/nuclear medicine research should be restored to the U.S. Department of Energy, says SNM, the worlds largest society for molecular imaging and nuclear medicine professionals.

Funded by the Department of Energy and the National Institutes of Health, the 13-month, $700,000 report was prompted by a $23 million cut in funding from the DOE Office of Sciences fiscal year 2006 budget, which effectively eliminated most money for basic nuclear medicine and molecular imaging research. The DOE has funded basic molecular imaging/nuclear medicine research since biomedical research was initially included in the Atomic Energy Act of 1954. This research has lead to the introduction of many life-saving technologies over the years. Advancing Nuclear Medicine Through Innovation recommends that the federal government enhance its commitment to nuclear medicine research since expanded use of nuclear medicine techniques has the potential to accelerate, simplify and reduce the costs of developing and delivering improved health care and could facilitate the implementation of personalized medicine.

The loss of funding for nuclear medicine research in the U.S. Department of Energy budget has been a tremendous blow to -- most importantly -- our current and future patients and our field, said SNM President Alexander J. McEwan, who represents 16,000 physicians, technologists and scientists. This report confirms that funding for this nations basic research program must be restored or future life-saving diagnostic and treatment procedures could be lost, he added.

If funding is not restored in the 2008 fiscal year, it will be detrimental to researchers and their labs. This is the only federal government research money dedicated to basic nuclear medicine research, and there are no plans to move this research to another federal agency, explai
'/>"/>

Contact: Maryann Verrillo
mverrillo@gmail.com
703-652-6773
Society of Nuclear Medicine
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Bioartificial kidney under study at MCG
2. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
3. W.M. Keck Foundation funds study of friendly microbes
4. Yellowstone microbes fueled by hydrogen, according to U. of Colorado study
5. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
6. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
7. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
8. Study Links Ebola Outbreaks To Animal Carcasses
9. Genome-wide mouse study yields link to human leukemia
10. Breakthrough Microarray-based Technology for the Study of Cancer
11. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...s inspired a 3.2m, three-year research project tha...security, energy and the environment. The Universi...QinetiQ have just signed a collaborative contract ...g physical sciences research. , Over the next t...y of Exeter and QinetiQ will work together to deve...
(Date:11/9/2009)...09 / b3c newswire / - Today, TNO, a Dutch contr...erican organization for contract research and cons... letter of intent with regard to TNOs dynamic in ...intent proposes a collaboration in which Seventh W...ion in North America. The TIM systems will be used...
(Date:11/9/2009)...leaders from around the world will gather in Bosto...ar Targets and Cancer Therapeutics International C...mation on important cancer therapies in developmen...it effectively we need a greater understanding of ...el," said Lewis Cantley, Ph.D., director of the ca...
Breaking Biology News(10 mins):£3.2m ($5.4 million) research project to capture brilliance of butterfly wings 2TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services 2Exponent to Announce Second Quarter 2009 Results 51709 1Elton John Billy Crystal Tony Bennett and Gladys Knight Help Starkey Hearing Foundation Raise More than 245 Million at Annual Fundraiser 51705 1Elton John Billy Crystal Tony Bennett and Gladys Knight Help Starkey Hearing Foundation Raise More than 245 Million at Annual Fundraiser 51705 2Elton John Billy Crystal Tony Bennett and Gladys Knight Help Starkey Hearing Foundation Raise More than 245 Million at Annual Fundraiser 51705 3Reminders Boost Mammography Appointments 51703 1Reminders Boost Mammography Appointments 51703 2
...ls have been little more than electronic versions ...the launch of PLoS ONE, which publishes primary re...pre- and post-publication peer review to maximize ...is published by the Public Library of Science (PLo...e the world,s scientific and medical literature a ...
...Many of them had narrow, pointed teeth, which were...wing them. But how did they then grind their food?... they were helped by stones which they swallowed. ...nd of ,gastric mill,. But this assumption does not...ties of Bonn and Tübingen have now proved. Their r...
... based on a combination of satellite data, compute...moke from Alaskan and Canadian forest fires as muc... away in Houston during a two-day period in July 2...in the Journal of Geophysical Research, offers sci...effects from pollutants generated thousands of mil...
Other Biology News:PLoS ONE is launched by the Public Library of Science 2PLoS ONE is launched by the Public Library of Science 3Dinosaurs -- stones did not help with digestion 2Dinosaurs -- stones did not help with digestion 3NASA study: Alaskan fires affected Houston air quality in 2004 2NASA study: Alaskan fires affected Houston air quality in 2004 3
(Date:11/6/2009)...G VALLEY, Calif., Nov. 6 Calbiotec... Small Business Innovative Research (SBIR) Phase I...terial command. Under terms of the agreement, Calb...s) for the diagnosis of Dengue virus. ,, Den...sents a major threat to military forces deployed t...
(Date:11/5/2009)...ERSBURG, Md., Nov. 5 Gen...ancial results for the third quarter ended Septemb...llion ($0.04 per share) for the three months ended... million ($0.08 per share) in the comparable quart..., 2009, GenVec,s net loss was $14.1 million ($0.15...
(Date:11/5/2009)...rence Call on Thursday, November 5, 2009 at 4:30 p...Nov. 5 /PRNewswire-FirstCall/ - OncoGenex Pharmace...AQ: OGXI ) today reported unaudited financial res...eptember 30, 2009 and reviewed the Company,s highl...lowing consolidated results reflect the operations...
(Date:11/5/2009)...IEGO, CA, November 5, 2009 /PRNewswire-FirstCall/ ...ed on using proprietary taste receptor-based techn...he food, beverage, and ingredient supply industrie...financial results for the third quarter ended Sept...e third quarter of 2009, compared to $4.0 million ...
Breaking Biology Technology:Calbiotech Awarded U.S. Army Phase I SBIR Research Contract to Develop Analyte Specific Reagents for the Diagnosis of Dengue Fever Virus 2GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 2OncoGenex Reports Third Quarter 2009 Financial Results 3OncoGenex Reports Third Quarter 2009 Financial Results 4OncoGenex Reports Third Quarter 2009 Financial Results 5OncoGenex Reports Third Quarter 2009 Financial Results 6OncoGenex Reports Third Quarter 2009 Financial Results 7OncoGenex Reports Third Quarter 2009 Financial Results 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14
...nference Call Tomorrow (Tuesday) at 8:30 am EDT to... Valley Cottage, NEW YORK, September 10 XTL,Biop...E: XTL) today announced,the initiation of a Phase ... norepinephrine reuptake inhibitor (SNRI) - for th...ine is being developed for the treatment of diabet...
...ltern, a leading global research,organization, is ...,Chiltern,s Country Manager for the Czech Republic...e year award. The award ceremony was held in,Londo...om amongst his peers by a panel of judges who,revi...ccessful conclusion,of clinical trials. The judgin...
Wyeth Sets Webcast and Conference Call for 2007 Third Quarter Earnings
Other Biology Technology:XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 2XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 3XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 4XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 5XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 6XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain 7Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year 2
Fingerprinting II Database Sharing Tools from Bio-Rad
Fingerprinting II Identification and Library Manager from Bio-Rad
DNA Engine Opticon 2 Continuous Fluorescence Detection System from Bio-Rad
...High Quality, Functionally-Validated, Ion Channel ...ng a critical role in nerve and muscle function an...d the heart. Drugs that modulate ion channels have...europathic pain, cardiac arrhythmia, hypertension,...
Biology Products: